Trial Design Webinars

31. Representative Trials Must Look Beyond Race And Ethnicity 7/23/2026

    Kemi Williams broadens the definition of representation to include geography, literacy, age, comorbidities, sexual orientation, gender identity, and other factors, emphasizing that trials must reflect the populations most affected by a disease.

32. Trial Design Choices Determine Who Gets Access 7/23/2026

    When asked what advice they have for sponsors, sites, or regulators, Natalie Monegro talks about the issues we can control from the onset of the trial that affect inclusiveness.

33. Education Is Essential To Representative Enrollment 7/23/2026

    According to Leida Bowen, the biggest challenge with inclusive trials is often education, helping colleagues and stakeholders better understand patient disparities and experiences so they can avoid unintentionally creating barriers to participation.

34. Patients Should Shape Trials Before Protocols Are Finalized 7/23/2026

    Leida Bowen explains how patient councils and early community input can inform protocol design, reduce burden, and ensure trials reflect patient needs before study execution begins.

35. This Isn't Just A Compliance Exercise 7/23/2026

    Natalie Monegro argues that representative enrollment is a scientific imperative, not merely a compliance exercise, and explains why sponsors need to show how trial data will be used to support real-world treatment and commercialization.

36. Why Representation Is More Than A Diversity Checkbox 7/23/2026

    Kemi Williams explains the distinction between diversity and representation, using the donanemab Alzheimer’s trial as an example of how underrepresentation can create real clinical and labeling consequences.

37. The Impact Of GLP-1s On Cardiovascular Clinical Development 7/23/2026

    As GLP-1 use expands, cardiovascular research is evolving. Discover key trial design considerations, development trends, and insights driving cardiometabolic innovation.

38. The Evolution Of GLP-1s: Overcoming Clinical Development Challenges 7/23/2026

    Explore clinical development trends, recruitment hurdles, study design strategies, and emerging therapies shaping obesity and metabolic disease research.

39. Stop Treating Patient Samples As Acceptable Losses 7/17/2026

    This short webinar excerpt pushes back on the idea that preventable biological sample loss should be tolerated as a routine part of trial execution.

40. How Sample Issues Can Cause Bioequivalence Studies To Fail 7/17/2026

    In this webinar excerpt, we learn why biological sample issues can have such an outsized impact in bioequivalence studies.